ACTRN12605000396628招募中2 期
A Phase II study to evaluate the safety and histological response to Rituximab in adults with Sjogren's Syndrome
St Vincent's Hospital / University of New South Wales0 个研究点目标入组 10 人开始时间: 2005年9月14日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- Female
入选标准
- •1. Sjogrens Syndrome according torecently updated European-American criteria, 2. Unchanged Sjogrens Syndrome for atleast 3 months 3. no aspirin or NSAID therapy within 7 days of each parotid or labial biopsy.
排除标准
- •1. radiation-induced xerostomia2. prior salivary gland surgery3. known parotid duct obstruction4. anticholinergic and sympathomimetic therapy5. prior rituxmab therapylive vaccine within 4 week of therapy6. history of cancer, recurrent bacterial infections or immunodeficiency7.pregnacy or brest feeding8. lab abnormality at screening7.
研究者
相似试验
招募中
2 期
A Phase 2 Study of MK-3475A in Japanese Participants with Recurrent or Metastatic (R/M) or Locally Advanced (LA) unresectable Cutaneous Squamous Cell Carcinoma (cSCC)JPRN-jRCT2041230074Koh Yasuhiro19
终止
2 期
A 2-stage Phase II study of combination pomalidomide and low dose dexamethasone therapy in patients with relapsed myeloma previously treated wtih lenalidomide maintenance post Autologous Stem Cell Transplant (LEOPARD follow-on study)ACTRN12615000447550Alfred Health30
已完成
不适用
A clinical phase II study assessing the safety and efficacy of readministration of bendamustine monotherapy or bendamustine/rituximab for relapsed low grade B cell non-Hodgkin lymphoma or mantle cell lymphoma patients previously treated with bendamustine containing chemothearpylow-grade B cell non-Hodgkin lymphoma, Mantle cell lymphomaJPRN-UMIN000010923KEIO BRB Study Group38
进行中（未招募）
1 期
Investigate the efficacy and safety of study drug ABX464 50 mg once daily versus placebo with patients with moderate to severe Active Ulcerative Colitis.Moderate to severe Ulcerative Colitis.MedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856EUCTR2017-000937-30-PLABIVAX30
进行中（未招募）
1 期
Investigate the efficacy and safety of study drug ABX464 50 mg once daily versus placebo with patients with moderate to severe Active Ulcerative Colitis.Moderate to severe Ulcerative Colitis.MedDRA version: 20.0Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000016670EUCTR2017-000937-30-FRABIVAX30